Tel：028-88610620
Email：pr@keymedbio.com
● CMG901 for the treatment of gastric
cancer and gastroesophageal junction
adenocarcinoma was granted the
Orphan-drug Designation by the FDA.
● FDA granted CMG901 Fast Track
Designation for unresectable or metastatic
gastric and gastroesophageal junction
cancer which have relapsed and/or are
refractory to approved therapies.
Company Profile Management Team Milestones Corporate Culture
R&D Center Pipeline Manufacturing Park Cooperation Expanded Access Policy
Corporate Governance Information Disclosure Financial Reports Stock Information IR Calendar Investor Presentations Email Alerts
Latest News Media
Culture & Benefits
Contact Information Consultation Legal Statement Privacy
Tel：028-88610620
Email：pr@keymedbio.com
蜀ICP备2022006281号